← all works
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
Why is this work in the frame?
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
Canadian affiliationAn author listed a Canadian institution. This is the only route the usual frame has.
Abstract
No abstract. This is not a gap in this database — OpenAlex has none either. 23.3% of the frame is in this state, and the screen finds HALF as much metaresearch here, so the absence is a measured bias rather than a missing field.
The record
- Venue
- The Lancet
- Topic
- Cancer Immunotherapy and Biomarkers
- Field
- Medicine
- Canadian institutions
- Princess Margaret Cancer Centre
- Funders
- —
- Keywords
- PembrolizumabMedicineIpilimumabInternal medicineClinical endpointAdverse effectRefractory (planetary science)CohortClinical trialMelanomaResponse Evaluation Criteria in Solid TumorsGastroenterologySurgeryPhases of clinical researchCancerImmunotherapy
- Has abstract in OpenAlex
- no